Bristol-Myers Squibb - Chief Science Officer Interview.

Publication: Finance Wire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2006 Voxant, Inc.

Original Source: CNBC/DOW JONES BUSINESS VIDEO

JOE KERNEN, CNBC ANCHOR: Bristol-Myers Squibb received accelerated approval for Sprycel, it is a treatment for a rare form of leukemia known as CML. The drug is the first approved oral inhibitor for treating all phases of CML for patients that have developed resistance to prior therapies, including Gleevec, which is made by Novartis (NVS). Joining us "First on CNBC" is Elliott Sigal, chief science officer of Bristol-Myers Squibb.

And Bristol-Myers, as we know from Lance Armstrong and other advertising, was a leader in oncology. Lately maybe the Genentechs (DNA), the Amgens (AMGN), some other companies have gotten more -- had more success in recent years. Is this the beginning of Bristol-Myers` comeback (INAUDIBLE)?

ELLIOT SIGAL, CHIEF SCIENCE OFFICER, BRISTOL-MYERS SQUIBB: I think so. And I`m glad to be here. This is a very good day for patients who are suffering from chronic myeloid leukemia, because...

Read the full article for free courtesy of your local library.